- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01339403
Kaiser Permanente HIV Cohort Study
2 avril 2015 mis à jour par: ViiV Healthcare
Hiv Infection, Antiretroviral Therapy Use And Other Predictors Of Selected Clinical Events In Kaiser Permanente
Human Immunodeficiency Virus (HIV) infected patients in the Kaiser Permanente HIV registry wil be followed in the usual clinical care to estimate the rates of specified clinical events.
The rates will be stratified by relevant characteristics like age, CD4 counts, HIV Viral Load (VL), HIV medication history.
The rates in the HIV infected cohort wil be compared with the rates of these events in patients in the Kaiser Permanente database who are not infected with HIV.
Aperçu de l'étude
Description détaillée
All HIV infected patients in the database will be included without any sampling.
A random sample of non-HIV infected patients will be included as comparator.
Type d'étude
Observationnel
Inscription (Réel)
282368
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
18 ans et plus (Adulte, Adulte plus âgé)
Accepte les volontaires sains
Non
Sexes éligibles pour l'étude
Tout
Méthode d'échantillonnage
Échantillon non probabiliste
Population étudiée
HIV infected patients in the HIV Registry of Kasier Permanente Northern and Southern California and a matched cohort of non-HIV infected patients in Kaiser Permanente
La description
Inclusion Criteria:
HIV infection.
Exclusion Criteria:
None
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
---|---|
HIV infected
No study specific intervention, non-interventional trial
|
No study specific intervention, non-interventional trial
|
HIV-uninfected
No study specific intervention, non-interventional trial
|
No study specific intervention, non-interventional trial
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Incidence Rate of Malignancies
Délai: Up to Week 835
|
Incidence rate of malignancies was calculated as the number of events divided by person-time.
Only the first diagnosis of each event per participant was included.Person-time was calculated as the sum of all time contributed by each individual who were Kaiser Permanente (KP) member from the date of HIV care initiation at that institution or January 1, 1996 for KP Northern California(KPNC) and January 1, 2000 for KP Southern California(KPSC) if in care prior to this date.
Malignancies included acquired immunodeficiency syndrome (AIDS)-defining malignancies and non-AIDS defining malignancies.AIDS-defining malignancies included invasive cervical cancer,invasive non-Hodgkin's lymphoma and kaposi's sarcoma;non-AIDS defining malignancies cancers ascertained from the KP cancer registries.Overall data for non-AIDS and AIDS defining malignancies, along with individual data for AIDS-defining malignancies was reported.
Incidence rate was computed as the number of events per 100,000 person-years.
|
Up to Week 835
|
Incidence Rate of Myocardial Infarction and Ischemia
Délai: Up to Week 835
|
Incidence rate of cardiovascular (CVS)events including myocardial infarction (MI) and ischemia was calculated as the number of events divided by person-time.
Only the first diagnosis of each event per participant was included.
Person-time was calculated as the sum of all time contributed by each individual who were KP member from the date of HIV care initiation at that institution or January 1, 1996 for KPNC and January 1, 2000 for KPSC if in care prior to this date.
Incidence rate was computed as the number of events per 100,000 person-years.
|
Up to Week 835
|
Incidence Rate of Acquired Immunodeficiency Syndrome (AIDS)-Defining Opportunistic Infections
Délai: Up to Week 835
|
Incidence rate of AIDS-defining opportunistic infections (OI) was calculated as the number of events divided by person-time.Only the first diagnosis of each event per participant was included.Person-time was calculated as the sum of all time contributed by each individual who were KP member from the date of HIV care initiation at that institution or January 1,1996 for KPNC and January 1,2000 for KPSC if in care prior to this date.OI were those that occurred on immune-compromised participants.AIDS-defining infections included:wasting syndrome;pneumocystis jirovecii pneumonia;recurrent pneumonia;cytomegalovirus;HIV-related encephalopathy;esophageal candidiasis;mycobacterium avium complex;cryptococcosis;mycobacterium tuberculosis;progressive multifocal leukoencephalopathy;lung candidiasis;toxoplasmosis of brain;coccidiomycosis;histoplasmosis;recurrent salmonella septicemia;chronic isosporiasis;cryptosporidiosis.Incidence rate was computed as the number of events per 100,000 person-years.
|
Up to Week 835
|
Incidence Rate of Liver Failure
Délai: Up to Week 835
|
Incidence rate of liver failure was calculated as the number of events divided by person-time.
Only the first diagnosis of each event per participant was included.
Person-time was calculated as the sum of all time contributed by each individual who were KP member from the date of HIV care initiation at that institution or January 1, 1996 for KPNC and January 1, 2000 for KPSC if in care prior to this date.
Incidence rate was computed as the number of events per 100,000 person-years.
|
Up to Week 835
|
Incidence Rate of Liver Related Death
Délai: Up to Week 835
|
Incidence rate of liver related death was calculated as the number of events divided by person-time.
Only the first diagnosis of each event per participant was included.
Person-time was calculated as the sum of all time contributed by each individual who were KP member from the date of HIV care initiation at that institution or January 1, 1996 for KPNC and January 1, 2000 for KPSC if in care prior to this date.
Incidence rate was computed as the number of events per 100,000 person-years.
|
Up to Week 835
|
Incidence Rate of Rhabdomyolysis
Délai: Up to Week 835
|
Incidence rate of Rhabdomyolysis was calculated as the number of events divided by person-time.
Only the first diagnosis of each event per participant was included.
Person-time was calculated as the sum of all time contributed by each individual who were KP member from the date of HIV care initiation at that institution or January 1, 1996 for KPNC and January 1, 2000 for KPSC if in care prior to this date.
Incidence rate was computed as the number of events per 100,000 person-years.
|
Up to Week 835
|
Incidence Rate of All-Cause Mortality
Délai: Up to Week 835
|
Incidence rate of all-cause mortality was calculated as the number of events divided by person-time.
Only the first diagnosis of each event per participant was included.
Person-time was calculated as the sum of all time contributed by each individual who were KP member from the date of HIV care initiation at that institution or January 1, 1996 for KPNC and January 1, 2000 for KPSC if in care prior to this date.
Incidence rate was computed as the number of events per 100,000 person-years.
|
Up to Week 835
|
Incidence Rate of Viral Encephalitis
Délai: Up to Week 730
|
Incidence rate of viral encephalitis (VE) was calculated as the number of events divided by person-time.
Only the first diagnosis of each event per participant was included.
Person-time was calculated as the sum of all time contributed by each individual who were KP member from the date of HIV care initiation at that institution or January 1, 1996 for KPNC and January 1, 2000 for KPSC if in care prior to this date.
Incidence rate was computed as the number of events per 100,000 person-years.
The participants with viral encephalitis were followed-up up to 31st December 2009 (730 Weeks).
|
Up to Week 730
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Publications et liens utiles
La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude
1 février 2009
Achèvement primaire (Réel)
1 octobre 2013
Achèvement de l'étude (Réel)
1 octobre 2013
Dates d'inscription aux études
Première soumission
16 mars 2011
Première soumission répondant aux critères de contrôle qualité
19 avril 2011
Première publication (Estimation)
20 avril 2011
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
3 avril 2015
Dernière mise à jour soumise répondant aux critères de contrôle qualité
2 avril 2015
Dernière vérification
1 avril 2015
Plus d'information
Termes liés à cette étude
Autres numéros d'identification d'étude
- A4001105
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur VIH
-
Icahn School of Medicine at Mount SinaiIRRASRecrutementHémorragie intraventriculaire (HIV)États-Unis
-
Yale UniversityComplétéPrématurité | Nourrissons de très faible poids à la naissance | Hémorragie intraventriculaire (HIV) | Saignement dans le cerveauÉtats-Unis
Essais cliniques sur non-interventional trial
-
GE HealthcareComplété
-
RadiancyComplétéLombalgie chronique légère à modéréeIsraël
-
Johns Hopkins UniversitySheikh Khalifa Stroke InstituteRecrutementAccident vasculaire cérébral | Faiblesse de la mainÉtats-Unis
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI)RecrutementInfections à VIH | Cancer | Malignité liée au VPH | Cancer anal | Tumeur maligne associée au VIH | Lymphome lié au SIDA | Sarcome de Kaposi lié au SIDA | Malignité liée au SIDAÉtats-Unis
-
Nantes University HospitalComplétéArrêts cardio-respiratoires préhospitaliers | Récupération spontanée de l'activité circulatoireFrance
-
University of British ColumbiaUniversity of OttawaActif, ne recrute pas
-
Hitit UniversityComplété
-
Dr. Lutfi Kirdar Kartal Training and Research HospitalComplété
-
Purdue UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Complété
-
Massachusetts General HospitalPas encore de recrutement